Method for inhibiting platelet aggregation

• US 6,770,660 B2
• Filed: 05/01/2003
• Issued: 08/03/2004
• Est. Priority Date: 05/06/2002
• Status: Expired due to Term

• Current Assignee: Medicure International, Inc. (Medicure, Inc.)
• Original Assignee: Artery, LLC
• Inventors: Schneider, David, DiBattiste, Peter M.
• Primary Examiner(s): Henley, III, Raymond J.
• Application Number:
  US10/427,436
• Publication Number:
  US 20030207918A1
• Time in Patent Office: 460 Days
• Field of Search: 514/331
• US Class Current: 514/331
• CPC Class Codes: A61K 31/4465 only substituted in position 4
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of about 25 μg/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 μg/kg/min, wherein the active drug is tirofiban or a salt thereof.

Claims

1. A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of about 25 μ

g/kg, and

     2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 μ

g/kg/min, wherein the active drug is tirofiban or a salt thereof.

2. A method of claim 1, wherein the salt is tirofiban hydrochloride.

3. A method of claim 2, wherein the amount of tirofiban hydrochloride in the bolus injection is 25 μ

g/kg.

4. A method of claim 3 wherein the intravenous infusion is between 12 hours and 72 hours.

5. A method of claim 4 wherein the intravenous infusion is between 18 hours and 72 hours.

6. A method for reducing the risk of acute coronary syndrome in a patient at risk to acute coronary syndrome, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of about 25 μ

g/kg, and

     2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 μ

g/kg/min, wherein the active drug is tirofiban or a salt thereof.